LPCN

+ Watchlist + Portfolio

Lipocine Inc.

Regulated industry Physical productsTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $2.07
52-Week Range: $1.81 – $12.37
Market Cap: $16.90M
P/E (TTM): —
EPS (TTM): -1.85
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 0.78
PEG Ratio: —
Return on Equity: -60.94%
Return on Assets: -37.04%
Gross Margin: 100.00%
Operating Margin: -1495.14%
Profit Margin: 0.00%
Current Ratio: 11.48
Debt/Equity: 0.01
Total Debt: $257.81K
Free Cash Flow: $-6.94M
Revenue Growth: -69.50%
Earnings Growth: —
Enterprise Value: $-6.11M

LPCN Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$500.00K	-$2.85M	$11.20M	$1.98M
Cost of Revenue	$8.56M	$10.18M	$7.35M	$8.58M
Gross Profit	-$8.06M	-$13.03M	$3.85M	-$6.61M
Selling, General & Admin	$4.06M	$4.90M	$5.00M	$3.76M
Operating Expenses	$4.06M	$4.90M	$5.00M	$3.76M
Operating Income	-$12.12M	-$17.93M	-$1.16M	-$10.37M
EBITDA	-$10.72M	-$17.90M	-$1.11M	-$10.31M
Pretax Income	-$10.76M	-$16.35M	$9.03K	-$9.63M
Income Tax	$681.00	$755.00	$681.00	$200.00
Net Income	-$10.76M	-$16.35M	$8.35K	-$9.63M
Diluted EPS	-2.21	-3.14	0.00	-1.77
Diluted Shares	5.23M	5.27M	5.42M	5.71M

LPCN Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$3.15M	$4.77M	$6.21M	$5.21M
Receivables	$659.86K	$52.25K	$211.85K	$1.16M
Current Assets	$34.14M	$22.86M	$22.32M	$16.88M
Total Assets	$37.54M	$23.00M	$22.51M	$17.01M
Current Liabilities	$1.68M	$2.63M	$1.51M	$2.53M
Total Liabilities	$1.91M	$2.63M	$1.51M	$2.53M
Retained Earnings	-$183.43M	-$199.78M	-$199.77M	-$209.40M
Shareholders' Equity	$35.63M	$20.37M	$21.00M	$14.48M
Working Capital	$32.46M	$20.23M	$20.81M	$14.35M

LPCN Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$11.97M	-$11.87M	-$1.22M	-$9.76M
Capital Expenditure	-$133.83K	-$13.17K	-$90.09K	—
Free Cash Flow	-$12.10M	-$11.88M	-$1.31M	-$9.76M
Depreciation & Amortisation	$9.45K	$28.66K	$41.11K	$60.78K
Stock-Based Compensation	$636.14K	$654.44K	$408.55K	$242.50K
Investing Cash Flow	$14.29M	$13.08M	$2.45M	$5.89M
Financing Cash Flow	-$2.13M	$404.57K	$209.34K	$2.87M
Share Repurchases	-$21.70K	—	—	—
Net Change in Cash	$197.94K	$1.62M	$1.43M	-$1.00M

LPCN Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$93.86K	$622.85K	$114.57K	$1.15M	$119.40K	$190.10K
Cost of Revenue	—	$2.14M	—	—	—	$2.04M
Gross Profit	—	-$1.51M	—	—	—	-$1.85M
Research & Development	$1.06M	—	$2.71M	—	$2.76M	—
Selling, General & Admin	$1.12M	$890.43K	$767.84K	$983.39K	$1.20M	$990.96K
Operating Expenses	$2.18M	$890.43K	$3.48M	-$4.92M	$3.97M	$990.96K
Operating Income	-$2.09M	-$2.40M	-$3.36M	-$2.52M	-$3.85M	-$2.84M
EBITDA	-$2.07M	-$2.39M	-$3.35M	-$2.50M	-$3.83M	-$2.83M
Pretax Income	-$1.86M	-$2.21M	-$3.19M	-$2.37M	-$3.67M	-$2.62M
Income Tax	$200.00	$0.00	$0.00	$0.00	$0.00	$200.00
Net Income	-$1.86M	-$2.21M	-$3.19M	-$2.37M	-$3.67M	-$2.62M
Diluted EPS	-0.35	-0.41	-0.59	—	-0.54	-0.32
Diluted Shares	5.35M	5.35M	5.41M	—	6.80M	8.22M

LPCN Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$3.35M	$6.04M	$3.90M	$5.21M	$5.02M	$4.98M
Receivables	$179.03K	$121.73K	$115.27K	$1.16M	$230.81K	$291.16K
Current Assets	$20.33M	$18.42M	$15.93M	$16.88M	$25.24M	$23.74M
Total Assets	$20.50M	$18.58M	$16.07M	$17.01M	$25.36M	$23.84M
Current Liabilities	$1.30M	$1.45M	$1.93M	$2.53M	$2.53M	$2.07M
Total Liabilities	$1.30M	$1.45M	$1.93M	$2.53M	$2.53M	$2.07M
Retained Earnings	-$201.63M	-$203.84M	-$207.03M	-$209.40M	-$213.07M	-$215.69M
Shareholders' Equity	$19.20M	$17.13M	$14.14M	$14.48M	$22.83M	$21.77M
Working Capital	$19.03M	$16.97M	$14.00M	$14.35M	$22.72M	$21.67M

LPCN Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$1.97M	-$1.89M	-$2.99M	-$2.92M	-$2.26M	-$3.03M
Free Cash Flow	-$1.97M	-$1.89M	-$2.99M	-$2.92M	-$2.26M	-$3.03M
Depreciation & Amortisation	$15.57K	$16.11K	$14.12K	$14.98K	$14.81K	$14.65K
Stock-Based Compensation	$71.00K	$65.20K	$53.26K	$53.03K	$65.40K	$58.15K
Investing Cash Flow	-$882.07K	$4.50M	$701.45K	$1.57M	-$9.90M	$1.48M
Financing Cash Flow	$0.00	$75.62K	$141.33K	$2.65M	$11.97M	$1.51M
Net Change in Cash	-$2.85M	$2.69M	-$2.14M	$1.30M	-$190.23K	-$36.18K

Market Snapshot

About

Lipocine Inc. is a specialty pharmaceutical company focused on developing innovative pharmaceutical products for metabolic and endocrine disorders. The company uses proprietary drug delivery technologies to create oral formulations of therapies traditionally delivered by injection. Lipocine targets conditions including hypogonadism, liver disease, and metabolic dysfunction.